Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023

The global proteinuria therapeutics market has the potential to grow by USD 81.83 million during 2019-2023. The growth momentum will accelerate throughout the forecast period and the market will grow at a CAGR of almost 3%.

The growing geriatric population and the introduction of smartphone-based diagnosis and treatment are some of the major factors driving market growth. The US, the UK, and Canada are currently the major markets for proteinuria therapeutics.

Proteinuria Therapeutics Market Report - Key Insights

Scope of this Report

The report provides a detailed analysis of the market by product and geography. Also, the proteinuria therapeutics market forecast report analyzes the market's competitive landscape and offers information on several market vendors.

Browse TOC and LoE with selected illustrations and example pages from proteinuria therapeutics market report

Request a FREE sample now!

Market Segmentation      

Proteinuria Therapeutics Market by Product

• ACE inhibitors
• ARBs
• Other therapeutics

Proteinuria Therapeutics Market by Region

• Asia
• Europe
• North America
• ROW

Market Competitive Analysis

The proteinuria therapeutics market is fragmented, and the degree of fragmentation will increase during the forecast period. With the rising kidney related diseases and other health issues, vendors and governmental bodies are taking efforts to increase awareness about various kidney diseases along with proteinuria. AbbVie Inc., AstraZeneca Plc, and Boehringer Ingelheim International GmbH are some of the major market participants. Though the accelerating growth momentum will offer immense growth opportunities, the lack of curative therapies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The report provides information on the production, sustainability, and prospects of several companies, including:

• AbbVie Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

Proteinuria Therapeutics Market: Key Drivers and Trends

The prevalence of proteinuria increases with age and the rapid advances in healthcare and the availability of advanced treatment options have increased the life expectancy of people, leading to a rise in the geriatric population. This will result in an increase in number of proteinuria cases, driving the need for effective therapeutics. Considering the potential usage of proteinuria, vendors are focusing on developing novel therapies to reduce proteinuria.

Moreover, proteinuria is also common among people with a history of renal diseases. Proteinuria can also be caused by diseases such as multiple myeloma, AIDS, lupus, and rheumatoid arthritis. The prevalence of these risk factors will also drive the need for proteinuria therapeutics over the forecast period.

• Protein therapeutics market trends such as the introduction of smartphone-based diagnosis and treatment will also influence market growth.
• Advances in technology help in increasing the adherence of patients to treatment. The proliferation of smartphone-based applications help in providing effective and quick results at lower costs.
• Smartphone-based applications are unique as they are autonomous and do not need a specialist to take clinical decisions.
• These advancements will help patients in identifying proteinuria and enable nephrologists in providing effective treatment.
• During 2019-2023, the market will register a CAGR of almost 3%.

Proteinuria Therapeutics Market: Segmentation by Region

For more insights on the proteinuria therapeutics market share of various regions Request for a FREE sample now!

North America is a major market for proteinuria therapeutics. The growing sales of off-label drugs and the increasing prevalence of various associated risk factors for proteinuria are driving market growth in the region. The high prevalence of the risk factors for proteinuria is also increasing the adoption of therapeutics for its treatment.

During the forecast period, over 51% of the overall market growth will originate from North America. However, market growth in this region will be slower than the growth of the market in Asia.

Proteinuria Therapeutics Market: Segmentation by Product

Request for a FREE sample and Get more information on the market contribution of various product segments

ACE inhibitors help to relax the veins and arteries to lower the blood pressure and prevent an enzyme in the body from producing angiotensin II which narrows the blood vessels. They are highly preferred by medicine manufacturers and clinicians. As a result, the proteinuria therapeutics market size will increase in this segment during the forecast period.

This proteinuria therapeutics market analysis report provides an accurate prediction of the contribution of various segments to the growth of the market.

Proteinuria Therapeutics Market: Key Highlights of the Report

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the market during the next five years
• Precise estimation of the global proteinuria therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the proteinuria therapeutics industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of proteinuria therapeutics companies 

We can help! Our analysts can customize this report to meet your requirements. Get in touch